AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Genmab Announces Positive Phase 3 EPCORE FL-1 Trial Results for Epcoritamab in R/R Follicular Lymphoma
ByAinvest
Thursday, Aug 7, 2025 10:32 am ET1min read
Genmab's Phase 3 EPCORE FL-1 trial met dual primary endpoints for relapsed/refractory follicular lymphoma (FL), demonstrating a 95.7% overall response rate and a 79% reduction in progression-free survival. The results will serve as the basis for global regulatory submissions. The US FDA has accepted the supplemental Biologics License Application for priority review, with a target action date of November 30, 2025. If approved, epcoritamab plus rituximab and lenalidomide would be the first bispecific antibody combination regimen available for second-line treatment in R/R FL.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet